Literature DB >> 9525838

A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas--an Eastern Cooperative Oncology Group Study (E2392).

R Hellman1, D S Neuberg, H Wagner, M Grunnet, H I Robins, D Karp, P Flynn, G Adams.   

Abstract

This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9525838     DOI： 10.1023/a:1005867520788

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  11 in total

1.  Cancer statistics, 1997.

Authors:  S L Parker; T Tong; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1997 Jan-Feb       Impact factor: 508.702

Review 2.  Does chemotherapy benefit the patient with a central nervous system glioma?

Authors:  L A Rodriguez; V A Levin
Journal:  Oncology (Williston Park)       Date:  1987-11       Impact factor: 2.990

3.  Statistical considerations for pilot studies.

Authors:  D Schoenfeld
Journal:  Int J Radiat Oncol Biol Phys       Date:  1980-03       Impact factor: 7.038

4.  VP-16, vincristine and procarbazine with radiation therapy for treatment of malignant brain tumors.

Authors:  R M Hellman; J A Calogero; B M Kaplan
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

5.  Etoposide (VP-16-213) in malignant brain tumors: a phase II study.

Authors:  U Tirelli; M D'Incalci; R Canetta; S Tumolo; G Franchin; A Veronesi; E Galligioni; M G Trovò; C Rossi; E Grigoletto
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

6.  Synergistic antitumor activity of vincristine and VP-16-213.

Authors:  D V Jackson; T R Long; T F Trahey; T M Morgan
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

Authors:  H A Fine; K B Dear; J S Loeffler; P M Black; G P Canellos
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

8.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch
Journal:  J Natl Cancer Inst       Date:  1993-05-05       Impact factor: 13.506

9.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.

Authors:  S B Green; D P Byar; M D Walker; D A Pistenmaa; E Alexander; U Batzdorf; W H Brooks; W E Hunt; J Mealey; G L Odom; P Paoletti; J Ransohoff; J T Robertson; R G Selker; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  Cancer Treat Rep       Date:  1983-02

10.  Lack of potentiation of vincristine-induced neurotoxicity by VP-16-213.

Authors:  D V Jackson; H B Wells; D R White; H B Muss; F Richards; M R Cooper; J J Stuart; E K Pope; C L Spurr
Journal:  Am J Clin Oncol       Date:  1983-06       Impact factor: 2.339
View more
  1 in total

Review 1.  Pharmacotherapy of malignant astrocytomas of children and adults: current strategies and future trends.

Authors:  M T Jennings; S Iyengar
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.